Previous 10 | Next 10 |
Energy Focus (NASDAQ:EFOI) +52% launches nUVo virus-targeted UVC air disinfectors to public. Lexaria Bioscience (NASDAQ:LEXX) +25% dehydraTECHTM-CBD reduces arterial stiffness, results confirmed in human clinical study HYPER-H21-2. Dare Bioscience (NASDAQ:DARE) +23% announces F...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks closed out the week with a decline, but managed to limit some damage with last-hour buying. The Nasdaq (COMP.IND) -1.9% took the brunt...
Olema Pharmaceuticals' (OLMA +10.2%) director BVF Partners has purchased 739,675 shares at $9.39/share. The total transaction values at $6.9M. SEC Filing. The company's 51.31% shareholdings are held by institutions: Earlier, As Olema falls 60% following data confusion, Street analysts re...
Omicron and the Federal Reserve combined to send stocks reeling on Tuesday, with the S&P dropping by nearly 2%. Department store chains exemplified the slide, with the added catalyst of a Sell rating for one of the industry's biggest players. Dillard's (NYSE:DDS) lost nearly a fifth of it...
Although shares of Olema Pharmaceuticals (NASDAQ:OLMA) fell 60% in trading today, two Street analysts remain bullish on the company's prospects. The plunge was precipitated by what Olema called a "falsified poster" released on social media yesterday afternoon dealing with early-stage data on ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adagio Therapeutics (NASDAQ: ADGI ) stock is rising higher on Tuesday as investors on social media can’t stop talking about the company. Source: Shutterstock Interest in ADGI stock is trending higher to...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Guardforce AI (NASDAQ: GFAI ) stock is running higher on Tuesday thanks to news of a deal with Hadyai CCC in Thailand. Source: Shutterstock.com This deal has Guardforce Cash Solutions Security, a subsidiary of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Olema Pharmaceuticals (NASDAQ: OLMA ) stock isn’t doing so hot on Tuesday following the release of results from a Phase 1/2 clinical trial. Source: Shutterstock According to a press release , Olema Pha...
Olema Pharmaceuticals (NASDAQ:OLMA)announced that three patients experienced a reduction in the tumor size (partial responses) out of 24 efficacy-evaluable patients in its ongoing Phase 1/2 clinical trial for OP-1250 against metastatic breast cancer and other women’s cancers. As of Nov...
Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals Robust anti-tumor activity, including three partial responses (two confirmed and one ...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...